HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

J. Biol. Chem., Vol. 275, Issue 27, 20700-20706, July 7, 2000

This Article Abstract Full Text (PDF) All Versions of this Article: 275/27/20700    most recent M909970199v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Datta, K. Articles by Mukhopadhyay, D. Search for Related Content PubMed PubMed Citation Articles by Datta, K. Articles by Mukhopadhyay, D. Social Bookmarking                      What's this?

Inhibition of Insulin-like Growth Factor-I-mediated Cell Signaling by the von Hippel-Lindau Gene Product in Renal Cancer^*

Kaustubh Datta, Raman Nambudripad^§, Soumitro Pal, Mi Zhou^¶, Herbert T. Cohen^¶, and Debabrata Mukhopadhyay

From the Departments of  Pathology and ^§ Molecular Computing Facility, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215 and ^¶ Renal Section, Boston University Medical Center, Boston, Massachusetts 02118

Received for publication, December 15, 1999, and in revised form, March 29, 2000

	ABSTRACT

TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS AND DISCUSSION REFERENCES

Insulin-like growth factor-I (IGF-I)-mediated signaling is thought to be involved in the regulation of multiple cellular functions in different tumors including renal cell carcinoma (RCC). Blocking IGF-I signaling by any of the several strategies abolishes or delays the progression of a variety of tumors in animal models. Herein, we demonstrate that in RCC cell lines, IGF-I-mediated signaling is found to be inhibited in the presence of wild type von Hippel-Lindau (VHL) tumor suppresser gene. Moreover, molecular modeling and biochemical approaches have revealed that -domain of the VHL gene product by interacting directly with protein kinase C inhibits its association with IGF-IR for downstream signaling. We also demonstrated that RCC has IGF-I-mediated invasive activity where protein kinase C is an important downstream molecule, and this invasiveness can be blocked by wild type VHL. These experiments thus elucidate a novel tumor suppresser function of VHL with its unique kinase inhibitory domain.

	INTRODUCTION

TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS AND DISCUSSION REFERENCES

Recent studies on renal cell carcinoma (RCC)¹ have mainly focused on identifying molecular prognostic factors, including growth factors (1, 2), oncogenes (3, 4), cell adhesion molecules (5, 6), and proteases (7, 8), that may provide insights into the mechanism of the cancer and its subsequent treatment. Insulin-like growth factors (IGFs) are candidate proliferation markers in renal cell carcinoma because of their overall importance in embryonic and somatic growth, differentiation, and tumorigenesis (9, 10) and because of their particular importance in renal growth and development (11, 12). Although IGFs are mainly secreted in the liver, its autocrine and paracrine activity is observed in most tissues (13, 14).

Most of the biological activities of IGFs are mediated through insulin-like growth factor-I receptor (IGF-IR). The ligand IGF-I triggers an intrinsic tyrosine kinase activity in the receptor, resulting in its autophosphorylation and the presentation of its substrate binding sites (15). Substrates containing either the Src homology domain or phosphotyrosine-binding domain can interact with IGF-IR for various downstream signal transduction cascades that ultimately lead to cell proliferation, differentiation, antiapoptosis, and, in pathological conditions, tumor development (16, 17). Embryonic fibroblasts established from IGF-IR(/) mice resistant to transformation induced by different oncogenes, growth factor receptors, and viral proteins that can be reversed by reconstitution with wild type IGF-IR (17). Also blocking of IGF-IR signaling by any of the several strategies (antisense, dominant negative, or neutralizing antibody against IGF-IR) abolishes or delays the progression of a variety of tumors in animal models (18-20). In addition to its tumorigenic activity, IGF-I also has a role in tumor angiogenesis. Recently, it has been demonstrated that IGF-I promotes the expression of the potent angiogenic factor, vascular permeability factor/vascular endothelial growth factor in colon cancer (21). Thus any factor that can block IGF-I-mediated downstream signaling can potentially inhibit both tumerogenesis and angiogenesis. Recent studies have shown that protein kinase C (PKC) plays an important role in IGF-IR-mediated cell proliferation and transformation (22). It associates with IGF-IR and gets tyrosine phosphorylated, resulting in increased activity. It has also been demonstrated that the ATP-binding mutant of PKC can inhibit the transforming ability of IGF-I.

The von Hippel-Lindau (VHL) gene on chromosome 3p25-26 encodes a tumor suppresser protein of 30 kDa that has multiple functions, such as down-regulating hypoxia-inducible genes (e.g. angiogenic factor-like vascular endothelial growth factor and hypoxia-inducible factor), regulating cellular ubiquitination machinery and p27 proteins (23-26). Germ line mutations in human VHL gene lead to various VHL-associated diseases that predispose to different kinds of tumors such as renal cell carcinomas, pheochromocytoma, hemangioblastoma, and pancreatic cancer (27-29). The critical role of VHL in clear cell RCC has been confirmed by demonstrating that more than 70% of the sporadic RCCs have biallelic VHL mutations (30). Present studies on VHL indicated that wt-VHL binds with hCUL-2-elongin B/C complex (CBC complex), forming CBC^VHL, which may function as E3-type ubiquitin ligase because of their structural similarity with its yeast homologue SCF (31-34). Thus VHL helps ubiquitination of cellular proteins that are ultimately degraded by proteasome 26 S complex. Our previous studies have shown that the VHL gene product can directly interact with PKC (35), but here we did not find any decrease in PKC level in RCC cells that overexpress wt-VHL. Because PKC is an important downstream intermediary of IGF-I signaling cascade (22), we therefore hypothesized that apart from its role in ubiquitination machinery, VHL could play a significant inhibitory role by blocking the association of PKC and IGF-IR. In the present context, we demonstrate that, indeed the wt-VHL gene product inhibits IGF-IR/PKC interaction and thus inhibits IGF-I-induced cell proliferation. Moreover, we describe a novel domain of VHL that is responsible for PKC interaction and also suggests a new mechanism of VHL tumor suppresser function.

	MATERIALS AND METHODS

TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS AND DISCUSSION REFERENCES

Cell Culture-- Human renal carcinoma cell line (786-O) was maintained in Dulbecco's modified Eagle's medium with 10% fetal bovine serum (hyClone Laboratories). 786-O clonal cell lines stably transfected with either pRC (Neo cells; cells contain empty vector with neo cassette), pRC-HAVHL (VHL cells; cells expressing wt-VHL) pRC-HAVHL-(1-115), pCMVFLAGVHL, pCMVFLAGVHL (1-143) were grown in complete medium supplemented with G418 (1 mg/ml) (25). 786-O neo, 786-O HAVHL, and 786-O HAVHL- (1-115) were gifts from W. G. Kaelin.

Immunoprecipitations and Western Blot Analysis-- Cells were washed twice with 10 ml of cold phosphate-buffered saline, lysed with ice-cold lysis buffer (50 mM Tris, pH 7.5, 1% Nonidet P-40, 150 mM NaCl, 1 mM Na₃VO₄, 2 mM EGTA, 1 mM phenylmethylsulfonyl fluoride, 10 µg/ml leupeptin, 0.5% aprotinin, 2 mM pepstatin A), incubated for 10 min on ice, and centrifuged for 10 min at 4 °C. Immunoprecipitations were carried out in antibody excess, using 0.5 mg of total protein either with affinity-purified rabbit polyclonal antibody (1 µg of IgG) against PKC (Santa Cruz Biotechnology, Inc.) or with mouse monoclonal antibody (1 µg) directed against IGF-IR subunit (Santa Cruz Biotechnology, Inc.). Immunocomplexes were captured with protein A-agarose beads (Bio-Rad). After three washes with cell lysis buffer, bead-bound proteins were separated by SDS-polyacrylamide gel electrophoresis. Size-separated proteins were transferred (Trans-Blot SD; Bio-Rad) to a nylon membrane (Immobilon-P; Millipore). For immunodetection, membranes were blocked in washing buffer (phosphate-buffered saline and 0.1% Tween 20) with 4% milk and incubated in washing buffer with either IGF-IR monoclonal antibody (dilution, 1:1000; stock concentration, 0.2 mg/ml) or anti-VHL monoclonal antibody (dilution, 1:1000; stock concentration, 0.5 mg/ml; PharMingen) or anti-FLAG antibody (dilution, 1:1000; stock concentration, 4.4 mg/ml; Sigma) or PKC polyclonal antibody (dilution, 1:1000; stock concentration, 0.2 mg/ml). The secondary antibodies were goat anti-rabbit and anti-mouse Ig linked to horseradish peroxidase (Pierce) which were detected by chemiluminescence (Pierce).

Cell Proliferation Assay-- RCC 786-0 cells were plated in 24-well plates (1 × 10³ cells/well) and starved for 16 h in 1 ml of 0.1% fetal calf serum in Dulbecco's modified Eagle's medium. Antibodies against IGF-IR that specifically block the IGF-IR-mediated cell signaling and IgG as a control were added at different concentrations (2 µg or 10 µg/ml) simultaneously. After the incubation [³H]thymidine (0.5 µCi) were added directly to cell cultures for 4 h. Wells were then washed three times with cold phosphate-buffered saline, cells were then incubated in 5% ice-cold trichloroacetic acid for 15 min, then rinsed twice with 75% ethanol, and solubilized in 0.1 M NaOH for scintillation counting.

In Vitro Binding Assay-- Glutathione S-transferase-VHL protein fusions under the control of a lac operator (pGEX plasmids: Amersham Pharmacia Biotech) were expressed in Escherichia coli. Cell pellets were briefly sonicated in binding buffer (20 mM Tris-HCl, pH 7.5, 150 mM KCl, 1 mM EDTA, 0.5% Nonidet P-40). Cleared cell lysates were mixed with glutathione-Sepharose beads (Amersham Pharmacia Biotech) and rocked for 1 h at 4 °C. The beads were washed three times with binding buffer. Beads were then mixed with purified recombinant human PKC protein (Panvera) (50 ng) and bovine serum albumin (5 µg) as a carrier in binding buffer. Bound proteins were then resolved in SDS-polyacrylamide gel electrophoresis and subjected to Western blotting against anti-PKC antibody.

Protein Kinase Assay-- Different GST-fused VHL proteins or the peptides were suspended in 50 µl of kinase reaction buffer (100 mM Tris-HCl, pH 7.5, 125 mM MgCl₂, 25 mM MnCl₂, 2 mM EGTA, 0.25 mM sodium orthovanadate, 2 mM dithiothreitol) containing 50 µM ATP (1 µCi) and histone (160 µg/ml) as substrate. Incubation with the enzyme PKC (concentration, 0.3 µg/ml) was at 30 °C for 30 min. The reaction was stopped by addition of 10 µl of 25% trichloroacetic acid. Precipitates were collected on P-81 filter paper (Whatman Co.). The filters were washed with 0.75% orthophosphoric acid and counted for ³²P using liquid scintillation spectroscopy.

In Gel Competitive Binding Assay-- Peptides (1 mg/ml) were immobilized to ultraLink Iodoacetyl bead (1 ml) (Pierce) according to manufacturer's protocol. 50 µl of peptide bound bead was incubated with recombinant human PKC (50 ng) in the buffer (50 mM Tris-HCl, 5 mM EDTA, pH 8.5) for 1 h at 4 °C. After thorough washing with the same buffer, bound PKC was eluted from the immobilized peptide bead by the other or same soluble peptides using batch elution method. All the washings and eluted fractions were collected and subjected to SDS-polyacrylamide gel electrophoresis followed by immunoblotting.

Invasion Assay-- A thin layer of Matrigel solution (0.040 ml of a 8 mg/ml stock solution; Becton Dickinson Labware) was overlaid on the upper surface of the 6.5-mm Transwell chambers (8-µm pore size; CoStar). The Matrigel was allowed to gel by incubating the plates for ~4 h at room temperature. Dulbecco's modified Eagle's medium (0.6 ml) containing 0.5 µM of IGF-I (Sigma) was then added to the bottom chamber of the transwells. Cells were resuspended in 0.2% bovine serum albumin/Dulbecco's modified Eagle's medium at a concentration of 2 × 10⁵/ml, and 2 × 10⁴ cells were added to the top well of the transwell chambers. In some experiments, IGF-1R-specific antibodies (1H7, 25 µg/ml) or a nonspecific mouse IgG control (25 µg/ml) were added to the cells and incubated for 1 h before the cells were plated on the top of the transwells. Cells were then incubated for 5 h in the CO₂ incubator. The cells that had not invaded through the matrigel were removed from the upper surface using cotton swabs, and the cells that had invaded through the matrigel and entered into the lower surface of the filters were fixed in methanol and then stained with a 0.2% solution of crystal violet in 2% ethanol. Invasion was quantitated by counting using bright field optics with a Nikon Diaphot microscope equipped with a 16-square reticle. The surface area of this grid was determined to be 1 mm². Three separate fields were counted for each filters.

Transient Transfection Assay-- Transient transfection of expression vector (pGEFPC1) containing dominant negative of PKC (PKC KR; point mutation of lysine 376 to arginine) or the empty vector alone to the 786-O cells was carried out with Effectene reagent (Qiagen) as directed by the manufacturer's protocol. We used a DNA:Effectene ratio of 1 µg of DNA to 25 µl of Effectene reagent in 60-mm dishes and 0.2 µg of DNA to 5 µl of Effectene reagent in each well of 24-well plate. The dominant negative of PKC (PKC KR) was a generous gift from R. Dutta.

	RESULTS AND DISCUSSION

TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS AND DISCUSSION REFERENCES

By co-immunoprecipation experiments using antibodies against PKC, we found that IGF-IR and PKC are in the same immunocomplex in two different 786-O clonal cell lines (Neo cells; cells contain empty vector with neo cassette, and without any wt-VHL; and VHL cells; cells express VHL-(1-115)) (25). Interestingly, in a 786-O clonal cell line stably transfected with pRC-HAVHL (wt-VHL cells; cells express wild type VHL), this immunocomplex was undetectable (Fig. 1A). These results suggest that in wt-VHL-containing cells, much less IGF-IR is associated with PKC as compared with renal cancer cells where wt-VHL is missing. Through immunoblot analysis it appears that the IGF-IR expression level is lower in VHL containing cell as compared with that of other cell lines. But densitometric scanning of the IGF-IR protein level detected in immunoblot suggests that the ratio of IGF-IR expressed in VHL containing cell line to other cell lines (which is 0.7) is significantly higher than that of IGF-IR associated with PKC (the ratio is 0.067) in these two cell lines. These data also might imply that VHL can regulate the protein expression level of IGF-IR to some extent. We did not find any difference in the protein level of PKC in any of these clonal cell lines, which also indicate that the direct interaction of PKC and VHL does not lead to ubiquitination and subsequent degradation of PKC (Fig. 1A). The immunoblot with anti-VHL antibody (Fig. 1A) shows the relative expression level of the wild type and VHL in their respective cell lines.

View larger version (44K): [in this window] [in a new window]   Fig. 1.   Inhibition of association between IGF-IR and PKC in presence of wt-VHL in RCC and its growth dependence on IGF-I. A, immunoprecipitation (IP) followed by immunoblot analysis (IB) were carried out using cell lysates of stable transfected RCC cell lines. Neo, empty neo cassette containing parental cell line where wt-VHL is missing; VHL, contains wt-VHL, and VHL contains VHL-(1-115). The right-hand panel indicates the immunoblot analysis with anti-VHL antibody using cell lysates of stable transfected VHL and VHL-(1-115) cell lines. B, growth inhibition experiments of RCC cell line were performed using anti-IGF-IR antibody. The percentage of incorporation of each experiment was determined by comparison with [3H]thymidine values from control (serum-starved RCC cells without any treatment) samples. Results are averages of three independent experiments.

To investigate whether the inhibition of IGF-IR signaling can block renal cell proliferation, we utilized IGF-IR antibodies that specifically inhibit IGF-I-mediated cell proliferation. Fig. 1B shows that the blocking antibody indeed inhibited IGF-I-dependent cell proliferation in a dose-dependent manner in an RCC cell line. The [³H]thymidine incorporation in control (in cpm) was 4707 ± 388; whereas in the presence of 2 µg/ml and 10 µg/ml of anti-IGF-IR antibody, the values were 2726 ± 368 and 448 ± 85, respectively. Therefore, the renal cancer cells have a dependence on IGF-I for their growth, whereas the presence of wt-VHL might be playing an inhibitory role on IGF-IR-mediated cell proliferation. Of importance, it has been described previously that wt-VHL has growth suppressive ability of renal carcinoma cell lines in addition to its antiangiogenic effect (36, 37). Therefore, our results suggest that wt-VHL prevents the association of IGF-IR with PKC and thereby inhibits the IGF-IR-mediated signaling pathways.

To determine the region of VHL that binds to PKC, we used different deletion mutants of GST-fused VHL. It was found that both the N-terminal mutant of VHL, i.e. VHL-(1-115) (VHL) and VHL-(1-122) can bind PKC along with wild type (wt-VHL) (Fig. 2A), whereas no interaction was detected with VHL-(1-89), VHL-(120-213) or VHL-(157-189), the latter known to be the elongin-binding domain from the crystal structure (38). So it can be concluded from this experiment that an N-terminal part of VHL outside the amino acid region 1-89 is responsible for binding with PKC. The lower panel in Fig. 2A shows the relative expression level of different GST-fused VHL derivatives bound to the bead. During review of this manuscript, a paper by Okuda et al. (46) also showed that the -domain of VHL also interacts with atypical PKC isotypes.

View larger version (48K): [in this window] [in a new window]   Fig. 2.   Biochemical and molecular modeling analysis of PKC and VHL interaction. A, immunoblot (IB) analysis with anti-PKC antibody after incubating different GST-fused VHL mutants with recombinant human PKC (50 ng). One-twentieth the amount of PKC used in the binding buffer was included for comparison (X0.2). The lower panel indicates the Ponceau staining of the blot showing the expression level of different GST-fused VHL mutants. B, protein kinase assays were performed of PKC using histone as a substrate in the presence of different GST-fused VHL mutant proteins. Fold activation of each experiment was determined by comparison with [-32P]ATP incorporation in presence of histone alone. Results are averages of three independent experiments. All experiments are done at least thrice. C, molecular model of the interaction of VHL with PKC. Space-filling model of the complex with Elongin B and Elongin C using WebLab Viewer Lite, v3.20. (Molecular Simulations, Inc., San Diego, CA). Blue, PKC; white, VHL; green, Elongin B; orange, Elongin C. D, environment of cofactor MgATP. E, ionic interactions that stabilize the complex. C and D were drawn using Molscript (43).

The PKC family of proteins consists of a regulatory domain and a catalytic domain. The regulatory domain of the various isoenzymes of PKC varies widely in size and sequence and presumably serves to confer specificity to the enzyme. The catalytic domain, on the other hand, is not only highly homologous to each other but also resembles other protein kinases, in particular cAMP-dependent protein kinase (PKA). These kinases are known to be involved in the phosphorylation of Ser or Thr residues of a large number of proteins. In PKA the catalytic domain consists of two lobes that are involved in binding to MgATP and the peptide substrate, respectively (39). A comparison of the phosphorylation sites has shown the importance of basic residues, in particular Arg, flanking the phosphorylated residue. The catalytic activity of protein kinases can be inhibited by protein kinase inhibitors as well as by the regulatory subunit of the kinases themselves. Two different classes of regulatory subunits exist: the RI-subunit class, which is not phosphorylated, and the RII-subunit class, which is autophosphorylated. A comparison of the sequence of the R-subunit of the kinases shows the presence of a segment resembling the substrate but differing in a few residues that are crucial for inhibition (40).

We were unable to detect any phosphorylation of wt-VHL or its mutants by PKC (data not shown), suggesting that VHL is not a substrate for PKC. The high degree of amino acid sequence similarity of the region (106-112) of VHL with the naturally occurring protein kinase inhibitors, however, suggests that this region has a good potential for being a kinase inhibitor of PKC (Table I). To investigate the inhibitory role of VHL on PKC, we performed kinase assays for PKC using histone as a substrate in the presence of wt-VHL or its different deletion mutants. The inhibitory activity closely followed the results obtained with the PKC binding assay; wt-VHL, VHL-(1-115) and VHL-(1-122) inhibited the kinase activity of PKC, whereas VHL-(1-89), VHL (120-213) and the elongin binding domain of VHL, VHL-(157-189), did not show any inhibitory activity (Fig. 2B). These results again suggest that the N-terminal domain of VHL indeed has an important role in the binding and inhibition of PKC. On the other hand, it is difficult to understand why the VHL-(1-115) mutant shows binding affinity and kinase inhibitory activity to PKC, whereas 786-O cells containing this mutant did not show any reduction in complex formation of IGF-IR with PKC.

Molecular modeling studies were carried out to understand the mechanism of inhibition of PKC by VHL at the molecular level. Recently, the x-ray crystal structure of VHL in association with Elongin B and C was determined (38). The structure of VHL reveals an N-terminal domain at residues 63-154 with a predominantly -structure and an -helical domain to residue 204. The interactions of VHL in the complex are through the -domain, which packs against the helices of Elongin C. The -domain, on the other hand, makes very little contact with the Elongins. We propose that the segment of VHL that interacts with PKC- (residues 105-122) lies in this domain, and we further present a model for this interaction.

Although the three-dimensional structure of PKC is not known, a molecular model for the catalytic domain can be built by homology modeling with PKA. A sequence alignment of the catalytic domains of PKA and four representative members of the PKC family (, , , and ) (Table II) shows their high homology particularly within the secondary structural regions. We used the program LOOK from Molecular Applications Group on a Silicon Graphics Octane workstation to obtain a preliminary model for PKC based on the structure of PKA obtained from the Protein Data Bank (code 1atp). Because of high sequence homology between catalytic domains of PKC and PKA (residue identity of 30%), the backbone of the modeled structure follows that of PKA very closely with a low RMS deviation of the C atoms (0.34).

View this table: [in this window] [in a new window]   Table II Amino acid sequence of the family of PKCs aligned with PKA, using Lasergene from DNASTAR Identical residues are shown in red, and similar residues are in blue. Schematic diagram of the secondary structures of the kinases is also presented here.  represents the - strand and  represents the -helix.

The x-ray crystal structure of VHL was obtained from the Protein Data Bank (code 1vcb). A scan of the VHL sequence against the PROSITE data base (41) identified a 9-residue segment (¹⁰⁵TGRRIHSYR¹¹³) closely resembling the consensus sequence of the phosphorylation site. As shown in Table I, the tetrapeptide TGRR is also contained in the inhibitor segment that was co-crystallized with PKA. The conformation of the tetrapeptide is very similar in the two structures: a -turn followed by an extended strand. Our strategy for initial positioning of VHL within the active site of PKC was therefore to align the tetrapeptide in VHL with the corresponding segment in the inhibitor peptide.

The docking of VHL with PKC was carried out using QUANTA (Molecular Simulations, Inc., San Diego, CA) on a Silicon Graphics Indigo2 workstation. Energy minimization of each molecule was carried out independently using CHARMm. The VHL molecule was manually moved, and the atoms of the TGRR segment were superposed on the corresponding atoms of protein kinase inhibitor, PKA. Iterative cycles of energy minimization and manual rotation of the side chain torsion angles were then performed to optimize the interactions between side chains of the two molecules.

The final model of VHL (Fig. 2, C and D) shows the N-terminal -sandwich of VHL fitting snugly into the cleft between the two lobes of PKC. The major interactions that stabilize the complex involve the two Arg side chains of the consensus phosphorylation site sequence, with Arg¹⁰⁷ making ionic contact with the carboxyl side chains of Asp³⁸⁴, Asp⁴²⁷, and Asp⁵⁸⁴, whereas Arg¹⁰⁸ is in close proximity to Asp⁴²³, Asp⁴²⁷, Asp⁴⁶³, and Glu⁴⁹⁰ (Fig. 2E). In the crystal structure of PKA, the Ala residue at the phosphorylation (P) position of the inhibitor peptide is close enough to the MgATP molecule so that an addition of a hydroxyl group (as in Ser or Thr) would enable it to interact with the -phosphate of ATP. In VHL the P position is occupied by His¹¹⁰, whose polar side chain can interact favorably with the phosphate, adding stability to the complex (Fig. 2D). Ser¹¹¹, on the other hand, points away from PKC and MgATP, which explains why it cannot be phosphorylated by PKC.

The binding experiment and the kinase inhibitory assay suggest that VHL-(1-115) can bind PKC and inhibits its activity in vitro. This observation can be explained by the molecular modeling data, which shows that the region 107-111 of VHL is the potential binding site to the catalytic domain of PKC. But we also found that VHL-(1-115) cannot block the association of PKC and IGF-IR in the 786-O cell line. To answer this anomaly we have synthesized two peptides derived from VHL amino acid sequence: (VHL-(100-118))CTLPPGTGRRIHSYGHLWL and (VHL-(105-123)) CTGRRIHSYRGHLWLFRDAG (additional Cs in the peptides are for coupling purpose with iodoacetyl matrix) and tested their kinase inhibitory function. Both the peptides were found to inhibit the kinase activity of PKC (Fig. 3A). Interestingly, VHL-(105-123) showed much greater kinase inhibitory activity compared with VHL-(100-118), although both contain the segment found to be essential for inhibition (106-111), suggesting that the region 115-123 has a distinct role in binding and down-regulating the catalytic activity of PKC. As a control experiment, an unrelated 30-amino acid peptide with no sequence similarity (CGKPPAPKPASPKKNIKTRSAQKRTNPKRV) to the two VHL peptides showed very little inhibition at higher concentrations (Fig. 3A).

View larger version (23K): [in this window] [in a new window]   Fig. 3.   Comparison of two different VHL-derived peptides to the abilities of kinase inhibitory activity and making stable complexes with PKC. A, kinase inhibition assays were performed of PKC using histone as a substrate in the presence of two different peptides derived from the VHL sequence, VHL(100-118; CTLPPGTGRRIHSYRGHLWL) and VHL(105-123; CTGRRIHSYRGH LWLFRDAG). A random 30-amino acid unrelated peptide (CGKPPAPKPASPKKNIKTRSAQKRTNPKRV) was used as control. Fold activation of each experiment was determined by comparison with [-32P]ATP incorporation in presence of histone alone. Results are averages of three independent experiments. B, binding affinity of recombinant PKC (50 ng) with the VHL peptides (in A) immobilized on iodoacetyl beads. The immunoblot analysis shows the amount of PKC present on the bead alone, bead covalently linked to VHL-(100-118), and bead linked to VHL-(105-123). Total input shows recombinant human PKC used as positive control. C, the lanes show the immunoblot of the eluants of PKC bound to each of the immobilized peptides, by the other or the same soluble peptides.

To further confirm the role of the segment 115-123 in substantially increasing the affinity of VHL for PKC, we performed in gel competitive binding assays. PKC was complexed with each of the VHL fragments 100-118 and 105-123, immobilized to a iodoacetyl bead (Fig. 3B), and eluted out using reciprocal soluble peptides. Fig. 3C shows that PKC can be eluted out only from the complex with VHL-(100-118) immobilized to iodoacetyl bead by free VHL-(105-123) peptide. Our studies therefore show the importance of the segment (115-123), and the molecular modeling results suggest that it binds to a region of PKC different from the catalytic domain. Interestingly, the VHL 96-122 region is also sufficient for the interaction of VHL with the Sp1 zinc finger domain, and, similarly, amino acids 112-122 are the most critical for binding (47). Because the regulatory domain of PKC contains cysteine-rich zinc-binding regions, it is possible that VHL binds to this region through the segment 115-123. Because this cysteine-rich region of PKC is only few amino acids apart from the autoregulatory domain, conformationally this domain of PKC should be very close to the catalytic subunit of the enzyme (42). Therefore, we hypothesize that VHL can bind to these two regions of PKC simultaneously, forming a very stable complex and inhibiting its catalytic activity. This tight binding is necessary for its inhibitory activity in vivo because it can compete only with the high affinity substrates for PKC. Thus, VHL-(1-115) can bind PKC in vitro, but it is competed out with other molecules in the cell because of its lower affinity, as in this case by IGF-IR. To confirm our hypothesis, we generated stable RCC cell lines containing VHL-(1-143) (without Elongin-binding sites but consisting of complete PKC-binding domain). Immunoprecipitation analysis reveals that VHL-(1-143)-containing cell lines completely inhibit PKC and IGF-IR interaction, and thus VHL-(1-143) functions as that of wt-VHL (Fig. 4). These results confirm that the extra amino acid (115-123) of VHL is important for the functional inhibition of IGF-I-mediated cell signaling. By immunoblot analysis it appears that the IGF-IR expression level is lower in VHL-(1-143) containing cell as compared with that of 786-0-neo cell line. Densitometric scanning of the IGF-IR protein level detected in immunoblot suggests that the ratio of IGF-IR expressed in VHL-(1-143) containing cell line to 786-0-neo cell line (which is 0.6) is significantly higher than that of IGF-IR associated with PKC (the ratio is 0.06) in these two cell lines. The immunoblot against anti-FLAG antibody (Fig. 4) shows the relative expression level of the wild type VHL and VHL-(1-143) in their respective cell lines.

View larger version (28K): [in this window] [in a new window]   Fig. 4.   Importance of -domain of VHL in inhibition of association between IGF-IR and PKC in RCC. Immunoprecipitation (IP) followed by immunoblot analysis (IB) were carried out using cell lysates from of stable transfected RCC cell lines, Neo, empty neo cassette containing parental cell line where wt-VHL is missing; VHL, contains wt-VHL; VHL(1-143), contains amino acids of VHL-(1-143). Utilizing other clones of VHL-(1-143) containing RCC we got the similar results. The right-hand panel indicates the immunoblot analysis with anti-FLAG antibody using cell lysates from stable transfected VHL and VHL-(1-143) cell lines.

The invasiveness of tumor cells is one of the important aspects of metastasis. Current findings (44, 45) have demonstrated that the invasive activity of some cancer cells is largely dependent on IGF-IR. Because IGF-IR is thought to play a major role in growth and development of RCC, we here tested whether RCC can show IGF-IR dependent invasive activity. Matrigel invasion assay clearly indicated that the invasive property of 786-O cells can be inhibited by blocking antibody against IGF-IR (Fig. 5A). Interestingly wild type VHL-containing cells showed poor invasive property compare with that of parental 786-O cells (Fig. 5B). So our data suggest that VHL, in addition to its inhibitory effect on vascular endothelial growth factor up-regulation and cell proliferation, can also inhibit the IGF-mediated invasiveness of RCC. Again when we transiently transfected dominant negative of PKC (PKC KR) to 786-O cells, a marked decrease in invasive activity was observed (Fig. 5C). Taken together these results suggest that the invasive activity of RCC is mediated through IGF-IR signaling where PKC is an important downstream molecule in this pathway and can be efficiently blocked by VHL.

View larger version (14K): [in this window] [in a new window]   Fig. 5.   . Matrigel invasion of 786-O cells. A, invasion of 786-O cells in presence of anti-IGF-IR antibody (25 µg/ml) that can specifically block IGF-IR signaling at a concentration of 25 µg/ml. Mouse IgG is used as a control. B, invasion of 786-O cells stably transfected with wild type VHL. 786-O cells stably transfected with the empty cassette (neo cell line) was used as a positive control. C, invasive activity of 786-O cells transiently transfected with dominant negative of PKC. 786-O cells transiently transfected with the empty vector acted as control. Results are averages of three independent experiments.

Various cellular proteins are found to be complexed with VHL protein that include Elongin B/C, Cullin-2(CUL-2), Rbx1, VHL-binding protein-1, hypoxia-inducible factor-1, etc. (31-34). All these interactions either help to form the ubiquitination machinery or lead to ubiquitination of cellular proteins that are ultimately degraded by proteasome 26 S complex. In this communication, we described a novel domain of VHL, is different from previous findings, that can be directly correlated to its tumor suppresser function by inhibiting IGF-I signaling pathways in renal cancer. On the other hand, our studies suggest an unique mechanism of inhibitory action of wt-VHL as a tumor suppressor and define a novel approach for designing anti-tumor drugs.

	ACKNOWLEDGEMENTS

We are thankful to W. Kaelin, B. Zbar, and R. Datta for reagents and J. Lawler, R. Khosravi-Far, and S. Basu for critical review of the manuscript.

	FOOTNOTES

^* This work was supported in part by National Institutes of Health Grant CA78383 (to D. M.) and under terms of a contract from the National Foundation for Cancer Research.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Eugene P. Schonfeld Medical Research awardee from National Kidney Cancer Association. To whom correspondence should be addressed: Dept. of Pathology, RN270H, Beth Israel Deaconess Medical Center and Harvard Medical School, 99 Brookline Ave., Boston, MA 02215. Tel.: 617-667-7853; Fax: 617-667-3591; E-mail: dmukhopa@caregroup.harvard.edu.

Published, JBC Papers in Press, March 29, 2000, DOI 10.1074/jbc.M909970199

	ABBREVIATIONS

The abbreviations used are: RCC, renal cell carcinoma; IGF, insulin-like growth factor; IGF-IR, IGF-I receptor; PKC, protein kinase C; VHL, von Hippel-Lindau; wt, wild type; GST, glutathione S-transferase; PKA, cAMP-dependent protein kinase.

	REFERENCES

TOP ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS AND DISCUSSION REFERENCES

CiteULike

Complore

Connotea

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				J. A. Sosman, I. Puzanov, and M. B. Atkins Opportunities and Obstacles to Combination Targeted Therapy in Renal Cell Cancer Clin. Cancer Res., January 15, 2007; 13(2): 764s - 769s. [Abstract] [Full Text] [PDF]

				C. Fottner, T. Minnemann, S. Kalmbach, and M. M Weber Overexpression of the insulin-like growth factor I receptor in human pheochromocytomas. J. Mol. Endocrinol., April 1, 2006; 36(2): 279 - 287. [Abstract] [Full Text] [PDF]

				E. Nakamura, P. Abreu-e-Lima, Y. Awakura, T. Inoue, T. Kamoto, O. Ogawa, H. Kotani, T. Manabe, G.-J. Zhang, K. Kondo, et al. Clusterin Is a Secreted Marker for a Hypoxia-Inducible Factor-Independent Function of the von Hippel-Lindau Tumor Suppressor Protein Am. J. Pathol., February 1, 2006; 168(2): 574 - 584. [Abstract] [Full Text] [PDF]

				W. Y. Kim and W. G. Kaelin Role of VHL Gene Mutation in Human Cancer J. Clin. Oncol., December 15, 2004; 22(24): 4991 - 5004. [Abstract] [Full Text] [PDF]

				W. G. Kaelin Jr. The Von Hippel-Lindau Tumor Suppressor Gene and Kidney Cancer Clin. Cancer Res., September 15, 2004; 10(18): 6290S - 6295S. [Abstract] [Full Text] [PDF]

				D. N. JACKSON and D. A. FOSTER The enigmatic protein kinase C{delta}: complex roles in cell proliferation and survival FASEB J, April 1, 2004; 18(6): 627 - 636. [Abstract] [Full Text] [PDF]

				T. Massfelder, H. Lang, E. Schordan, V. Lindner, S. Rothhut, S. Welsch, P. Simon-Assmann, M. Barthelmebs, D. Jacqmin, and J.-J. Helwig Parathyroid Hormone-Related Protein Is an Essential Growth Factor for Human Clear Cell Renal Carcinoma and a Target for the von Hippel-Lindau Tumor Suppressor Gene Cancer Res., January 1, 2004; 64(1): 180 - 188. [Abstract] [Full Text] [PDF]

				W. G. Kaelin Jr. The von Hippel-Lindau Gene, Kidney Cancer, and Oxygen Sensing J. Am. Soc. Nephrol., November 1, 2003; 14(11): 2703 - 2711. [Abstract] [Full Text] [PDF]

				K. Rodins, M. Cheale, N. Coleman, and S. B. Fox Minichromosome Maintenance Protein 2 Expression in Normal Kidney and Renal Cell Carcinomas: Relationship to Tumor Dormancy and Potential Clinical Utility Clin. Cancer Res., April 1, 2002; 8(4): 1075 - 1081. [Abstract] [Full Text] [PDF]

				K. Datta, C. Sundberg, S. A. Karumanchi, and D. Mukhopadhyay The 104-123 Amino Acid Sequence of the {beta}-domain of von Hippel-Lindau Gene Product Is Sufficient to Inhibit Renal Tumor Growth and Invasion Cancer Res., March 1, 2001; 61(5): 1768 - 1775. [Abstract] [Full Text]

This Article Abstract Full Text (PDF) All Versions of this Article: 275/27/20700    most recent M909970199v1 Alert me when this article is cited Alert me if a correction is posted